medigraphic.com
Colegio de Medicina Interna de México.

2010, Número 4

<< Anterior Siguiente >>

Med Int Mex 2010; 26 (4)


Breve reseña histórica de la enfermedad de Parkinson. De la descripción precipitada de la enfermedad en el siglo XIX, a los avances en Biología Molecular del padecimiento.

García S, López B, Meza DEG, Villagómez OAJ, Coral VR

Idioma: Español
Referencias bibliográficas: 51
Paginas: 350-373
Archivo PDF: 1534.03 Kb.


RESUMEN

Se presenta una reseña histórica de James Parkinson, de la enfermedad de Parkinson y un análisis sucinto de los avances en genética y biología molecular de la misma. Se realizó una búsqueda bibliográfica en los servidores de Google, Pubmed y Ovid utilizando las siguientes palabras: enfermedad de Parkinson, James Parkinson, historia de la enfermedad de Parkinson, genética y enfermedad de Parkinson, biología molecular en enfermedad de Parkinson, actualización en enfermedad de Parkinson. De más de 100,000 publicaciones obtenidas, sólo se eligieron las que históricamente compilaran la mayor parte de la información y los artículos médicos con nivel de evidencia I. De los metanálisis se eligieron 60 publicaciones para este trabajo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 2003;991:1-14.

  2. Abasolo-Osinaga E, Abecia-Inchaurregui LC, Fernandez- Diaz E et al. [The prevalence and pharmacological cost of Parkinson's disease in Spain]. Rev Neurol. 2006;43:641- 645

  3. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson’s Disease. NEUROLOGY 1997;48: 1277- 1281.

  4. Dekker MCJ, Bonifanti V, Duijn CM. Parkinson’s Disease, piecing together a genetic jigsaw. BRAIN 2003;126:1722- 1733.

  5. Tanner CM epidemiological clues to the cause of Parkinson’s Disease. In Marsden CD, Fahn S (EDS): Movement Disorders 3. Butterworth, Heinemann, Oxford (1994), pp124-7.

  6. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S et. Al. Prevalence of Parkinsonism and Parkinson’s Disease in Europe: the EuroParkinson collaborative study. European community concerted action on the Epidemiology of Parkinson’s Disease. J Neurol Neurosurg Psychiatry 1997; 62:10-15.

  7. Louis ED, Marder K, Cote l, Tang M, mayeux R. Mortality from Parkinson’s disease. Arch neurol 1997;54:260-264.

  8. Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back. Movement Disorders 2002;17(Suppl 3)S28-S40.

  9. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study. Neurology 1992;42;1142-1146.

  10. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745 752.

  11. Koller WC. How accurately can Parkinson’s disease be diagnosed? Neurology 1992;42(Suppl 1):6-16.

  12. Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch Neurol. 1999;56:33-39.

  13. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. ALA30PRO Mutation in the gene coding alpha-synuclein in Parkinson’s Disease. Nat Genet 1998;18:106-108.

  14. BenmoyaL-Segal L, Soreq H. Gene-environment in sporadic Parkinson disease. Journal of Neurochemistry 2006; 97:1740-1755.

  15. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JM, JAMA 1999; 281:341-346.

  16. Lücking CB, Dürr A, Bonifati V, Vangham J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000 May 25;342(21):1560-1567

  17. Morris HR: Genetics of Parkinson’s disease. Ann Med, 37:86- 96, 2005.

  18. Vidrio-Morgado H, Alonso-Vilatela ME, López López M. Factores genéticos involucrados en la susceptibilidad para desarrollar Enfermedad de Parkinson. Salud Mental 2007;30(1):16-24

  19. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston W. Parkinson’s disease in twins: An etiologic study. JAMA 1999;281:341-346.

  20. Gao X, Martin ER, Liu Y et al. Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18. Am J Hum Genet. 2009;84:499-504.

  21. Marder, MD MPH, G. Levy, MD, E. D. Louis, MD MS, H. Mejia– Santana, MS, L. Cote, MD, H. Andrews, PhD, J. Harris, PhD MS, C. Waters, MD FRCP, B. Ford, MD FRCP, S. Frucht, MD, S. Fahn, MD and R. Ottman, PhD. Accuracy of family history data on Parkinson’s disease, Neurology 2003;61:18-23

  22. Sveinbjornsdottir S, Hicks AA. Jonsson T, Potursson H, Gumundsson G, Frigge ML, et al. Familial aggregation of Parkinson’s disease in Iceland. N Engl J Med 2000;343:1765- 70.

  23. Alonso ME, Otero E, D'Regules R, Figueroa HH. Parkinson's disease: a genetic study. Can J Neurol Sci. 1986 Aug;13(3):248-51.

  24. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;27;276(5321):2045-7

  25. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. a-Synuclein in Lewy bodies Nature 1997;388:839-840

  26. Lücking CB, Brice A. Alpha-synuclein and Parkinson’s disease. Cell. Mol. Life Sci 2000;57:1894–1908.

  27. Valente M, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1.Science. 2004 May 21;304(5674):1120-1122.

  28. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E. Et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Scince 2003 Jan 10;299(5604):256-9.

  29. Satake W, Nakabayashi Y, Mizuta I et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303- 1307

  30. Mullen SA, Crompton DE, Carney PW, Helbig I, Berkovic F. A neurologist's guide to genome-wide association studies. Neurology. 2009;72:558-565.

  31. Twyman RM. SNP discovery and typing technologies for pharmacogenomics. Curr Top Med Chem. 2004;4:1423-1431.

  32. Chen J, Chatterjee N. Exploiting Hardy-Weinberg equilibrium for efficient screening of single SNP associations from casecontrol studies. Hum Hered. 2007;63:196-204

  33. Eng J. Sample size estimation: how many individuals should be studied? Radiology. 2003;227:309-313.

  34. Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat. 2005;26:63-68

  35. Darvasi A, Shifman S. The beauty of admixture. Nat Genet. 2005;37:118-119.

  36. Lang AE, Lozano AM. Parkinson’s Disease (first of two parts) N Engl J Med 1998;1044-1053.

  37. Burke RE. Programmed cell death and Parkinson’s disease. Mov Discor 1998;13(Suppl 1):17-23.

  38. Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease. NEUROLOGY 2008;70 (13):1916-1925.

  39. Hodaie M, NeimatJS, Lozano AM. The Dopaminergic Nigrostriatal system and Parkinson’s disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery 2007;60:17-30.

  40. Brighina L, Frigerio R, Schneider NK, Lesnick TG, De Andrade M, Cunningham JM, Farrer MJ, Lincoln SJ, et al.. Synuclein, pesticides, and Parkinson disease. A case– control study. NEUROLOGY 2008;70:1461–1469.

  41. Zeviane M, Di Donato S. Mitochondrial disorders. Brain 2004;127:2153-2172

  42. Bryan Sykes Mitochondrial DNA and . Studies of mitochondrial dna can solve genetic and historical riddles, as bryan sykes explains. htp ://genome .welcome .ac .uk /doc _ WTD020876.html .

  43. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease. Human Molecular Genetics, 2005; 14 (18):2749– 2755.

  44. Simon DK, Mayeux R, Marder K, Kowall NW, Beal MH, Johns DR. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson’s disease. Neurology 2000;54:703–9.

  45. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JPJ, Davis RE, Parker WD. Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann Neurol 1996;40:663–671

  46. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV,Cookson MR, Greenamyre TJ. An In Vitro Model of Parkinson’s Disease: Linking Mitochondrial Impairment to Altered_- Synuclein Metabolism and Oxidative Damage. Journal of Neuroscience 2002, 22(16):7006–7015

  47. Todd B. Sherer TB Betarbet R, Testa CM, Boo Seo B, Richardson JR, Kim JH, Miller GW, Yagi T, AkemiMatsuno- Yagi, Greenamyre JT. Mechanism of Toxicity in Rotenone Models of Parkinson’s Disease. Journal of Neuroscience 2003;23(34):10756 –10764

  48. Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, et al. Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease. Am. J. Hum. Genet. 200; 72:804–811.

  49. 49 Autere J, Moilanen JK,. Finnilä S, Soininen H, Mannermaa A, Hartikainen P, Hallikainen M, Majamaa K. Mitochondrial DNA polymorphisms as risk factors for Parkinson’s disease and Parkinson’s disease dementia. Hum Genet (2004) 115: 29–35

  50. 50 Ghezzi1 D, Marelli C, Achilli A, Goldwurm S, Pezzoli G, Barone P, Pellecchia MT. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson’s disease in Italians. European Journal of Human Genetics 2005;13:748–752

  51. 51 Huerta C, Castro MG, Coto E, Blázquez M, Ribacoba R, Guisasola LM. Mitochondrial DNA polymorphisms and risk of Parkinson’s disease in Spanish population. Journal of the Neurological Sciences 2005; 236:49–54




2020     |     www.medigraphic.com